CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On December 22, 2017, Marc Wilson notified Cidara Therapeutics, Inc. (the “Company”) of his resignation from his position as Principal Accounting Officer, effective as of January 3, 2018.

Matthew Onaitis, the Company’s current Principal Financial Officer, will assume the role of Principal Accounting Officer as of the effective date of Mr. Wilson’s resignation.

Mr. Onaitis has been serving as the Company’s Chief Financial Officer, General Counsel and Secretary since July 2016. There will be no change to Mr. Onaitis’ compensation arrangements with the Company as a result of his appointment as Principal Accounting Officer. There are no family relationships between Mr. Onaitis and any of the Company’s current or former directors or executive officers. Mr. Onaitis is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933.

About CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX)

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.